Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax

Rachael Milligan, Andre Daher, Gemma Villanueva, Hanna Bergman, Patricia M Graves

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)

Abstract

Background

Plasmodium vivax liver stages (hypnozoites) may cause relapses, prolonging morbidity, and impeding malaria control and elimination. The World Health Organization (WHO) recommends three schedules for primaquine: 0.25 mg/kg/day (standard), or 0.5 mg/kg/day (high standard) for 14 days, or 0.75 mg/kg once weekly for eight weeks, all of which can be difficult to complete. Since primaquine can cause haemolysis in individuals with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency, clinicians may be reluctant to prescribe primaquine without G6PD testing, and recommendations when G6PD status is unknown must be based on an assessment of the risks and benefits of prescribing primaquine. Alternative safe and efficacious regimens are needed.

Original languageEnglish
Article numberCD012656
Pages (from-to)CD012656
JournalCochrane Database of Systematic Reviews
Volume2020
Issue number8
DOIs
Publication statusPublished - 19 Aug 2020

Fingerprint

Dive into the research topics of 'Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax'. Together they form a unique fingerprint.

Cite this